Skip to content

Testosterone Therapy in Type 2 Diabetes Mellitus Patients with Erectile Dysfunction

Effects of Testosterone Therapy on Erectile Dysfunction in Type 2 Diabetes Mellitus Patients with normal level of Testosterone

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181106041575N1
Enrollment
66
Registered
2019-05-17
Start date
2018-08-23
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction. Male erectile disorder

Interventions

Intervention 1: Intervention group: intramuscular injection of 250 mg testosterone each month for 3 consecutive months in addition of 20mg Tadalafil, 2-hour before each intercourse. Intervention 2: Co

Sponsors

Research and technology deputy of Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Presence of Erectile dysfunction Presence of Type 2 Diabetes Mellitus Normal Serum Testosterone level IIEF=<16

Exclusion criteria

Exclusion criteria: Contraindication for Tadalafil consumption including: Heart disease, Hypertension and Nitrocontin consumption Contraindication for Tadalafil consumption including: liver disorder and prostate cancer

Design outcomes

Primary

MeasureTime frame
Erectile dysfunction according to The International Index of Erectile Function (IIEF-5). Timepoint: International Index of Erectile Function (IIEF-5) was completed before, 3-month, and 6-month after the intervention. Method of measurement: erectile dysfunction according to The International Index of Erectile Function (IIEF-5).

Secondary

MeasureTime frame
The side-effects of the intervention. Timepoint: before and 3-month after the intervention. Method of measurement: the side-effects of the intervention was measured using laboratory findings including liver function test, complete blood count (CBC), liver function test (LFT), fasting blood sugar and Prostate-specific antigen (PSA).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEsmaeil Totonchi

Mashhad University of Medical Sciences

TOTONCHIE951@MUMS.AC.IR+98 51 3840 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026